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Hemophilia is an X-linked inherited disorder characterized by the deficiency of coagulation factors VIII/IX (FVIII/IX). World federation of hemophilia’s annual global 
survey indicates that the number of people with hemophilia in 
the world is 176,211 of which 140,313 are hemophilia A and rest 
is hemophilia B cases. In India, there are 13,448 patients with 
hemophilia A and 2176 with hemophilia B, which account for 
5-6% of the total, this number being only a fraction of cases since 
many cases go undiagnosed [1].
Severe hemophilia is defined as deficiency of coagulation 
factors VIII (FVIII) or IX (FIX) with circulating factor levels 
<1 IU/dl [2]. It manifests as recurrent bleeding into muscles and 
joints from an early age of life [3]. The first joint bleed in severe 
hemophilia generally occurs after the first 6 months of life and in 
the majority of cases by the second birthday [4]. The consequence 
of repeated bleeding into joints is the premature development of 
hemophilic arthropathy with chronic disability and poor quality 
of life (QoL) [2,5]. The treatment for bleeding in early days was 
with fresh frozen plasma or cryoprecipitate infusion, later with 
plasma-derived factor concentrates, and presently recombinant 
factor concentrates are being used widely [6]. Factor concentrates 
infused only during bleeding episodes are referred to as “on 
demand” therapy [7].
Various studies proved that development of arthropathy 
can be effectively prevented by prophylactic administration 
of factor concentrates, by maintaining steady level of factor 
VIII levels >1 IU/L [7-10]. Prophylaxis with coagulation factor 
concentrate was pioneered for hemophilia A in the late 1950s 
and in hemophilia B in the early 1970s in Sweden [6]. There are 
various regimens of prophylactic therapy; all intended to maintain 
a steady level of coagulation factors in blood to avoid bleeding 
and its complications and disability [5] (Fig. 1). Prophylaxis has 
therefore been recommended by the World Health Organization 
and World Hemophilia Federation since 1994 and primary 
prophylaxis started after the first joint bleed and/or before 2 years 
is now evidence-based first-choice treatment in children with 
severe hemophilia [6].
Although prophylaxis, in general, is expensive, resource 
intensive and time-consuming, the overall economic savings 
from improved QoL with no bleeding and bleeding related 
complication should be more than enough to off-set the costs of 
implementation [11]. While “high-dose” regimens (25-40 IU/kg 
3 times a week) are considered as “gold standard” “intermediate 
dose” regimens (20-40 IU/kg, 2-3 times/week) have shown 
comparable QoL with reduction in hemoarthrosis at the expense of 
2-fold higher factor consumption [6,11,12]. Even this intermediate 
dose regimen is clearly not affordable in developing countries. 
Few studies in India, China and Thailand are providing evidence 
that even low dose prophylaxis (8-10 IU/kg, twice a week) can 
have major impact on number of bleeds, QoL and full participation 
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in society [12-15]. Although evidence on the benefits of low-dose 
prophylaxis from large clinical trials is yet to be proven, this may 
be the feasible way to deliver prophyaxis in developing country 
like ours [11]. We, at our center, started using the “intermediate 
regimen” due to (i) logistics of “supply-demand” and (ii) to get 
full patient compliance for the prophylaxis.
Very few centers in India are presently using recombinant 
factor VIII concentrate for hemophilia children as “on demand” 
therapy. “Prophylactic” therapy is yet to be implemented in most 
centers for this children due to financial constraints and logistics 
of giving this injection thrice weekly even though the benefits 
of this form of treatment is well established and is implemented 
in all developed countries. This study was undertaken to know 
the efficacy of intermediate dose prophylaxis with recombinant 
FVIII/IX concentrate in reducing the annual hemarthrosis rate 
(AHR).
MATERIALS AND METHODS
A retrospective observational study was conducted on children 
enrolled in our Hemophilia clinic of Department of Pediatrics, 
Employees State Insurance Corporation Post-graduate Institute of 
Medical Sciences and Research who initially received on “demand 
therapy” for 1 year and later changed over to “prophylaxis” with 
recombinant coagulation factor concentrate, 20 IU/kg of factor 
VIII/IX twice a week, for the next 1 year. Institutional Ethical 
Committee approval was taken for the study. Children under 
18 years of age with severe hemophilia A/B (serum coagulation 
factor VIII/IX activity <1%) were included the study. Children 
with poor compliance and dropouts or those who developed 
inhibitors were excluded from the study. Utilizing hospital records 
and patients dairy, AHR of these children while on “on demand” 
therapy and “prophylaxis” was calculated.
RESULTS
Out of 24 children enrolled to our hemophilia clinic, 14 children 
fulfilling inclusion criteria were considered for the study, their 
records and dairies were analyzed. Of these children 2 developed 
inhibitors (suspected clinically and confirmed by biochemical 
estimation of inhibitor levels) [7], and 4 were irregular 
(noncompliant) for treatment; hence, these 6 were excluded 
from the study. The study group finally consisted of 8 children 
and among these 6 were diagnosed as hemophilia A and 2 were 
hemophilia B. AHR, defined as number of hemarthrosis per year 
requiring factor replacement therapy, for a period of 1-year during 
on “demand therapy” was compared with AHR for a period of 
1-year on prophylaxis with FVIII/IX as shown in Fig. 2.
Age of children with hemophilia A at enrolment for 
prophylaxis with FVIII concentrate ranged from 4 years 1 month 
to 15 years with a mean of 9 years and age of children with 
hemophilia B for prophylaxis with FIX concentrate were aged 
6 years to 7 years with a mean of 6.5 years. It was observed 
that AHR in children with hemophilia A/B during “on demand” 
therapy was significantly more than that during prophylaxis with 
FVIII/IX concentrate, respectively, i.e., average of 13/year during 
on demand versus 1.6/year during prophylaxis in hemophilia A 
children and average of 7/year during on demand versus 1/year 
during prophylaxis in hemophilia B children.
We also observed a significant reduction in other bleeding 
manifestation such as psoas muscle bleed, epistaxis, oral bleeds, 
number of target joints involvement, and decrease in school 
absenteeism (Table 1 and Fig. 3). There was 87% and 85% 
reduction in AHR in hemophilia A and hemophilia B children, 
respectively. Hemarthrosis rate/participant/year was 2.5 and 0.32 
in on demand and prophylaxis group, respectively.
DISCUSSION
Nonrandomized as well as randomized studies have accumulated 
a plethora of data on prophylactic FVIII infusions in patients 
with severe hemophilia A/B, documenting the beneficial results 
of decreased bleeding episodes and later degenerative joint 
disease [6]. Difficulty of intravenous access in young children, lack 
of understanding on the part of the caregiver, fear of development 
of inhibitor, psychological factors, and not the least the exorbitant 
cost of recombinant factor therapy are some of the barriers to 
implement this form of therapy in severe hemophiliacs [6]. This 
form of therapy has not been widely practiced or standard of care 
in our country largely because of cost constraints. The percentage 
of children under 18 years on prophylaxis is estimated to be 
about 1%, and the majority of these children continue to receive 
Figure 1: Treatment options
Figure 2: Study flow chart
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plasma-derived factor concentrate as “on demand” therapy [1]. 
As an exception to these prevailing circumstances, children 
with severe hemophilia of insured persons of Employees State 
Insurance Corporation, India, are provided with recombinant 
FVIII/FIX concentrate free of cost ensuring a bright future for 
these children.
In our study on 8 children with severe hemophilia, mean 
age at starting factor concentrate prophylaxis was 9 years in 
Hemophilia A and 6.5 years in Hemophilia B. There was 87% 
reduction in AHR in Hemophilia A and 85% reduction in AHR 
in Hemophilia B during prophylaxis compared to “on demand” 
therapy. Hemarthrosis rate/participant/year was 2.5 and 0.32 in 
on demand and prophylaxis group, respectively. Manco-Johnson 
et al. [16] showed annual bleed rates of 4.35 and 0.2 per year 
among on demand and prophylaxis group, respectively. Gringeri 
et al. [17] (the ESPRIT study) observed that the AHR was 5.5 and 
1 in episodic/on demand treatment and prophylaxis, respectively. 
Verma et al. [12] showed that hemarthrosis rate among “on 
demand” treatment group was 0.48/patient/month (5.7/year) and 
prophylaxis group was 0.08/patient/month (0.96/year). Similar 
results have also been reported by other investigators [18-22].
At least 4 studies on children and adults from Thailand, China 
and India have shown superiority of low dose (~5–10 IU/kg, 
2-3 times a week) prophylaxis over episodic treatment in terms 
of bleed reduction, and QoL, with improved physical activity, 
independent functioning, school attendance and community 
participation [12-15]. Prophylaxis can still be individualized to 
affordability and higher protective trough level can be achieved 
using smaller doses given more frequently without an increase 
in consumption/cost. Thus, future studies proving this low dose 
therapy as feasible alternative may make prophylaxis universally 
available in resource-poor countries like ours.
New factor preparations with extended half-life are in 
clinical studies. If proven effective, such factor concentrates will 
significantly decrease the frequency of factor infusions, thus likely 
increasing compliance. Gene therapy, now under investigation, 
constitutes a possible alternative to prophylaxis, with curative 
potential [6]. Our study has some limitations being a single center 
study involving small group and due to short duration of the study. 
Further large trials are needed to generalize the study results.
CONCLUSIONS
Prophylaxis with coagulation factor concentrate reduces 
hemorrhagic events, and hence, reduces acute and chronic 
complication of repeated bleeding. Thus most of the centers caring 
for hemophilia have started prophylaxis with Factor concentrate. 
In our country, because of resource constraints very few centers 
have started prophylaxis, ours being one such pioneering center 
and this study reinforces the efficacy of prophylaxis.
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